Gain-of-function KRAS mutations that lead to constitutive activation of the MAPK pathway play a critical role in the initiation and maintenance of pancreatic cancer (frequency about 65%), highlighting this pathway as a pharmacological target in this disease [3,12]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.